Dr. Reddy's Laboratories, Inc.

125 articles with Dr. Reddy's Laboratories, Inc.

• Dr. Reddy's Laboratories Announces the Launch of Lenalidomide Capsules in the U.S. With Two of Six Strengths Eligible for First-to-market, 180-day Exclusivity

  9/7/2022

  Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch, in the U.S. market, of Lenalidomide Capsules, a therapeutic equivalent generic version of REVLIMID® (lenalidomide) Capsules approved by U.S. Food and Drug Administration (USFDA).

• Dr. Reddy's Laboratories enters into a licensing agreement with Slayback Pharma to obtain exclusive rights in the first-to-file ANDA for the private label version of Lumify® in the U.S.

  7/29/2022

  Dr. Reddy’s Laboratories Ltd. today announced that it has entered into a licensing agreement with Princeton, New Jersey based Slayback Pharma LLC (“Slayback”), to acquire rights in Slayback’s Brimonidine Tartrate Ophthalmic Solution 0.025%, the private label equivalent of Lumify® in U.S. Lumify® is an over-the-counter (OTC) eyedrop that can be used to relieve redness of the eye due to minor eye irritations.

• Dr. Reddy's Laboratories Announces the Launch of Fesoterodine Fumarate Extended-Release Tablets in the U.S. Market

  7/8/2022

  Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) announces the launch of Dr. Reddy’s Fesoterodine Fumarate Extended-Release Tablets, a therapeutic generic equivalent to Toviaz® (fesoterodine fumarate) Extended-Release Tablets in the U.S. market following the approval by the U.S. Food and Drug Administration (USFDA).

• Dr. Reddy's Laboratories Announces the Acquisition of an Injectable Product Portfolio from Eton Pharma

  6/24/2022

  Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced that it has acquired a portfolio of branded and generic injectable products from Deer Park, Illinois based-Eton Pharmaceuticals, Inc. (NASDAQ: ETON).

• Dr. Reddy's Laboratories Announces the Launch of Pemetrexed for Injection USP, in the U.S. Market

  5/27/2022

  Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Pemetrexed for Injection, 100 mg and 500 mg Single-Dose Vials, the generic equivalent of ALIMTA® (pemetrexed for injection) in the U.S. Market approved by the U.S. Food and Drug Administration (USFDA).

• Dr. Reddy's Laboratories and Senores Pharmaceuticals, Inc. announce the launch of Ketorolac Tromethamine Tablets USP, 10 mg in the U.S. market

  5/24/2022

  Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) and Senores Pharmaceuticals, Inc. today announced the launch of Ketorolac Tromethamine Tablets USP, 10 mg, a therapeutic generic equivalent of the reference listed drug Toradol Tablets, 10 mg in the U.S. market approved by the U.S. Food and Drug Administration (USFDA).

• Dr. Reddy's Laboratories Announces the Launch of Posaconazole Delayed-Release Tablets in the U.S. Market

  4/20/2022

  Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Posaconazole Delayed-Release Tablets, 100 mg, the therapeutic generic equivalent to NOXAFIL® (posaconazole) Delayed-Release Tablets, 100 mg approved by the U.S. Food and Drug Administration (USFDA).

• 

  Merck's Molnupiravir and the Monetary Cost of COVID-19

  10/5/2021

  There is a noted discrepancy between the price the U.S. government has agreed to pay Merck for the drug and the actual manufacturing costs.
• 

  Clinical Catch-Up: January 25-29

  2/1/2021

  It was a busy week for clinical trial news. Read on for more information.

• Dr. Reddy's and GRA Announce Clinically Meaningful Data from Avigan Pivotal Studies

  1/27/2021

  Dr. Reddy's Laboratories Ltd. (BSE: 500124) (NSE: DRREDDY) (NYSE: RDY) (NSEIFSC: DRREDDY along with its subsidiaries together referred to as "Dr. Reddy's") and Global Response Aid FZCO (GRA) today announced results from an Avigan study on moderate-severe hospitalized COVID-19 patients in Kuwait.

• Dr. Reddy’s Receives Approval to Conduct Phase 3 Clinical Trial for Sputnik V Vaccine in India

  1/15/2021

  Dr. Reddy’s Laboratories Ltd (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) announced today that it has received approval from the Drugs Control General of India (DCGI) to conduct phase 3 clinical trial for the Sputnik V vaccine in India. The phase 3 study of Sputnik V will be conducted on 1500 subjects as part of the randomized, double-blind, parallel-group, placebo-controlled study in India. Earlie

• Sputnik V meets the primary endpoint of safety in the Phase 2 Clinical Trial in India

  1/11/2021

  Dr. Reddy’s Laboratories Ltd. announced that the independent Data and Safety Monitoring Board has reviewed the safety data from the phase 2 clinical trial of the Sputnik V vaccine and recommended the phase 3 recruitment and continue the clinical trial without any modifications.

• Dr. Reddy's to Release Q3 FY 21 Results on January 29th, 2021

  1/8/2021

  Dr. Reddy's Laboratories Ltd. will announce results for the third quarter ended December 31, 2020 on Friday, January 29th, 2021 after the Board Meeting.

• 

  Biopharma Update on the Novel Coronavirus: December 1

  12/1/2020

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for December 1, 2020.

• Dr. Reddy's Laboratories Announces the Launch of Succinylcholine Chloride Injection USP, 200 mg/10 mL (20 mg/mL) in the U.S. Market

  11/12/2020

  Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Succinylcholine Chloride Injection USP, 200 mg/10 mL (20 mg/mL), Multiple-Dose Vials a therapeutic equivalent generic version of Quelicin® (Succinylcholine Chloride) Injection, 20 mg/mL, approved by the U.S. Food and Drug Administratio

• Dr. Reddy's to Release Q2 FY 21 Results on October 28th, 2020

  10/12/2020

  Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) will announce results for the second quarter ended September 30, 2020 on Wednesday, October 28th, 2020 after the Board Meeting.

• 

  Clinical Catch-Up: September 21-25

  9/28/2020

  The European Society of Medical Oncology (ESMO) Virtual Congress 2020 was last weekend and the beginning of the week, which resulted in numerous clinical trial announcements. Here’s a look.

• Dr. Reddy's Laboratories announces settlement of U.S. Revlimid® (lenalidomide) Capsules patent litigation with Celgene, a Bristol Myers Squibb Company

  9/17/2020

  Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”), today announced the settlement of their litigation with Celgene, a wholly owned subsidiary of Bristol Myers Squibb (NYSE: BMY), relating to patents for REVLIMID® (lenalidomide) Capsules.

• 

  Biopharma Update on the Novel Coronavirus: September 16

  9/16/2020

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 16, 2020.

• Dr. Reddy's Laboratories received approval of XEGLYZE™ (abametapir) lotion, 0.74%, in the U.S.  

  7/27/2020

  Dr. Reddy’s Laboratories Ltd. announced approval of XEGLYZE lotion, 0.74%, a 505 NDA by the U.S. Food and Drug Administration. The approval triggers the contractual pre-commercialization milestone of $20 million payable to Hatchtech Pty Ltd.